Benjamin Pullinger
YOU?
Author Swipe
View article: Clinical efficacy and safety of eravacycline for the treatment of enterococcal infections: a subpopulation analysis
Clinical efficacy and safety of eravacycline for the treatment of enterococcal infections: a subpopulation analysis Open
Background Infections due to Enterococcus faecalis and Enterococcus faecium are common in the hospital setting and carry a high risk for morbidity and mortality. Furthermore, the incidence of drug-resistant phenotypes, such as vancomycin-r…
View article: Eravacycline use in immunocompromised patients: multicenter evaluation of timely versus late initiation on clinical outcomes
Eravacycline use in immunocompromised patients: multicenter evaluation of timely versus late initiation on clinical outcomes Open
Infections from multidrug-resistant (MDR) bacteria lead to worse outcomes in immunocompromised patients. Eravacycline (ERV) is effective against MDR gram-negative and gram-positive bacteria, but its effects in immunocompromised populations…
View article: Eravacycline, the first four years: health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022
Eravacycline, the first four years: health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022 Open
Eravacycline is a synthetic fluorocycline approved by the U.S. Food and Drug Administration in 2018. This study aimed to describe clinical and microbiological outcomes in addition to associated adverse effects of eravacycline used in U.S. …
View article: 633. Eravacycline Use in Immunocompromised Patients: Multicenter Evaluation of Clinical and Safety Endpoints
633. Eravacycline Use in Immunocompromised Patients: Multicenter Evaluation of Clinical and Safety Endpoints Open
Background Infections caused by multidrug-resistant (MDR) bacteria are an increasingly common public health threat associated with worse outcomes in immunocompromised patients. Eravacycline (ERV) has potent in-vitro activity against MDR Gr…
View article: Clinical Outcomes of Eravacycline in Patients Treated Predominately for Carbapenem-Resistant Acinetobacter baumannii
Clinical Outcomes of Eravacycline in Patients Treated Predominately for Carbapenem-Resistant Acinetobacter baumannii Open
Acinetobacter baumannii , particularly when carbapenem resistant (CRAB), is one of the most challenging pathogens in the health care setting. This is complicated by the fact that there is no consensus guideline regarding management of A. b…
View article: 1288. Evaluation of Predictors for Clinical Success in Patients Treated with Eravacycline for Various Infections
1288. Evaluation of Predictors for Clinical Success in Patients Treated with Eravacycline for Various Infections Open
Background Eravacycline (ERV) is approved in the United States (US) for the treatment of complicated intra-abdominal infections in adults. We aimed to evaluate the independent predictors of clinical success in patients treated with ERV for…
View article: 1577. Real-World, Multicenter Experience with Eravacycline for Various Infections
1577. Real-World, Multicenter Experience with Eravacycline for Various Infections Open
Background Eravacycline (ERV) is Food and Drug Administration approved in patients for the treatment of adults complicated intra-abdominal infections in 2018. Real-world data regarding the indications for ERV use are is limited. We evaluat…
View article: Early Experience With Eravacycline for Complicated Infections
Early Experience With Eravacycline for Complicated Infections Open
Eravacycline (ERV) was used in 35 patients for various infections. The most common pathogen was Klebsiella pneumoniae, and 30-day survival was 74%. Absence of 30-day recurrence and resolution of signs and symptoms of infection were 91% and…